



Tabelecleucel for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease: Effectiveness and Value

Thursday • November 14, 2024 • 10:00 AM ET

Virtual Event – Zoom Webinar

Time (ET)	Activity
10:00 AM – 10:20 AM	Meeting Convened and Opening Remarks Sarah K. Emond, MPP President and CEO, ICER Steven D. Pearson, MD, MSc Special Advisor, ICER
10:20 AM – 11:00 AM	Presentation of the Clinical Evidence Grace Lin, MD, MAS Medical Director for Health Technology Assessment, ICER Associate Professor of Medicine and Health Policy, UCSF
11:00 AM – 11:40 AM	Presentation of the Economic Model Melanie Whittington, PhD, MSc Senior Fellow, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center
11:40 AM – 12:00 PM	Public Comments and Discussion
12:00 PM – 12:50 PM	Lunch Break
12:50 PM – 1:50 PM	NE CEPAC Vote on Clinical Effectiveness and Value
1:50 PM – 2:00 PM	Break
2:00 PM – 3:30 PM	Policy Roundtable
3:30 PM – 4:00 PM	Reflections from NE CEPAC
4:00 PM	Meeting Adjourned